Investorideas.com newswire, news and commentary for leading sectors

Wednesday, April 26, 2017

Aesthetic Medical Market News; RepliCel (OTCQB: $REPCF) (TSXV: $RP) Reports US Patent Issued for Novel Dermal Injection Technologies

Aesthetic Medical Market News; RepliCel (OTCQB: $REPCF) (TSXV: $RP) Reports US Patent Issued for Novel Dermal Injection Technologies



"We are confident RepliCel's extensive patent estate for its cell therapy and injection devices will provide our products with long-term market exclusivity," -Lee R. Buckler, CEO


VANCOUVER, BC - April 26, 2017 (Investorideas.com Newswire) Aesthetic Medical Market News alert ; RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the Company's novel, multi-needle dermal injection device.



Post a Comment

InvestorIdeas.com Newswire